Goldman Sachs analyst Issac Ro upgraded Abbott Labs (NYSE: ABT) from Neutral to Buy with a price target of $81.00 (from $78.00).
The analyst favors the company growth among peers, likes the disconnect between an underappreciated consensus expectation and his believes the company will accrue a favorable mix shift, the potential upside in the valuation, more favorable outlook for EPD/Nutritionals than consensus expects and share gains in Diagnostics following recent checks.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.